Menu

Blog

Archive for the ‘biotech/medical’ category: Page 1632

Mar 9, 2020

Magnetically guided non-invasive CRISPR-Cas9/gRNA delivery across blood-brain barrier to eradicate latent HIV-1 infection

Posted by in categories: biotech/medical, neuroscience

Scientific Reports volume 9, Article number: 3928 ( 2019 ) Cite this article.

Mar 9, 2020

Dogs, cats can’t pass on coronavirus, but can test positive

Posted by in categories: biotech/medical, food

HONG KONG — Pet cats and dogs cannot pass the new coronavirus on to humans, but they can test positive for low levels of the pathogen if they catch it from their owners.

That’s the conclusion of Hong Kong’s Agriculture, Fisheries and Conservation Department after a dog in quarantine tested weakly positive for the virus Feb. 27, Feb. 28 and March 2, using the canine’s nasal and oral cavity samples.

A unidentified spokesman for the department was quoted in a news release as saying. “There is currently no evidence that pet animals can be a source of infection of COVID-19 or that they become sick.”

Mar 9, 2020

Preventive Measures For Coronavirus (SARS-CoV-2, COVID-19)

Posted by in category: biotech/medical

Section 6 presents an emergency boost for the immune system at the beginning of a respiratory infection.


Learn some protective measures to consider in order to reduce your risk of contracting Coronavirus (COVID-19) and other viral illnesses.

Mar 9, 2020

Eye-Opening Treatments — Medical Frontiers-JAPAN Live & Programs

Posted by in categories: biotech/medical, life extension

3 minutes for glaucoma eye surgery.


Cataract and glaucoma are eye diseases that progress by aging. Both are severe diseases that can cause blindness, but in Japan, unique treatment methods and causes are being investigated. For cataracts, the world is paying attention to a Japanese doctor who has devised an innovative surgical method which is in just over 3 minutes. And distinctive research is progressing at Japanese universities as to what kind of ingredients can delay the progression of glaucoma. How can we save people from blindness? Explore with us the forefront of Japanese ophthalmic medical care.

Mar 9, 2020

Gene Therapy for Glaucoma

Posted by in category: biotech/medical

:oooo.


A novel approach to treat glaucoma is reported that achieves reduced intraocular pressure by combining intravitreal adeno-associated virus (AAV) gene delivery to the ciliary body with selective CRISPR-Cas9-mediated disruption of Aquaporin 1. Translational viability is assessed using both human ex vivo ciliary body cultures and two experimental mouse models.

Mar 9, 2020

CRISPR enhancement, coronavirus source and a controversial appointment

Posted by in category: biotech/medical

Crispr for coronavirus o.o


The latest science news, in brief.

Mar 9, 2020

CRISPR Pill May Be Key in Fight Against Antibiotic Resistance

Posted by in categories: biotech/medical, evolution

Even since Alexander Fleming stumbled across penicillin—the first antibiotic drug—scientists knew our fight with evolution was on.

Most antibiotics work by blocking biological processes that allow bacteria to thrive and multiply. With prolonged, low-dosage use, however, antibiotics become a source of pressure that forces bacteria to evolve—and because these microorganisms are extremely adept at swapping and sharing bits of their DNA, when one member becomes resistant, so does most of its population.

Continue reading “CRISPR Pill May Be Key in Fight Against Antibiotic Resistance” »

Mar 9, 2020

An experimental treatment for the new coronavirus is being tested in the US

Posted by in categories: biotech/medical, health

The National Institutes of Health is testing the antiviral drug remdesivir, which is also being studied in patients in China. Running trials during epidemics is tricky, but scientists learned a lot about how to conduct them during recent Ebola outbreaks.

Mar 9, 2020

Antiviral activity of itraconazole against type I feline coronavirus infection

Posted by in category: biotech/medical

Feline coronaviruses (FCoVs) are the causative agents of severe systemic disease (feline infectious peritonitis: FIP) in domestic and wild cats. FCoVs have been classified into serotypes I and II. Type I FCoV is the dominant serotype (approximately 70–90%) worldwide. Therefore, it is necessary to provide antiviral agents for type I FCoV infection. In this study, we demonstrated that itraconazole (ICZ), practically used for fungal infections in cats, inhibits the type I FCoV infection. ICZ also exhibited antiviral effect in cells after viral infection, suggesting that ICZ could potentially be used as a therapeutic.

Mar 9, 2020

NIH clinical trial of remdesivir to treat COVID-19 begins

Posted by in category: biotech/medical

Study enrolling hospitalized adults with COVID-19 in Nebraska.

Share to Print Print.